These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31670462)

  • 1. Pilot study on the effects of intravesical oxybutynin hydrochloride instillations on the validity of doping control urine samples.
    Walpurgis K; Scheiff AB; Welz M; Müller-Reul J; Webborn N; Görgens C; Guddat S; Fußhöller G; Dib J; Thevis M
    Drug Test Anal; 2019 Nov; 11(11-12):1755-1760. PubMed ID: 31670462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring 2-phenylethanamine and 2-(3-hydroxyphenyl)acetamide sulfate in doping controls.
    Sigmund G; Dib J; Tretzel L; Piper T; Bosse C; Schänzer W; Thevis M
    Drug Test Anal; 2015; 7(11-12):1057-62. PubMed ID: 26481102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N,N-dimethyl-2-phenylpropan-1-amine quantification in urine: application to excretion study following single oral dietary supplement dose.
    Wójtowicz M; Jarek A; Chajewska K; Kwiatkowska D
    Anal Bioanal Chem; 2016 Jul; 408(18):5041-7. PubMed ID: 27178556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Stimulants and Narcotics by Liquid Chromatography-Tandem Mass Spectrometry and Gas Chromatography-Mass Spectrometry for Sports Doping Control.
    Ahrens BD; Kucherova Y; Butch AW
    Methods Mol Biol; 2016; 1383():247-63. PubMed ID: 26660193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of designer doping agent--2-ethylamino-1-phenylbutane--in dietary supplements and excretion study following single oral supplement dose.
    Wójtowicz M; Jarek A; Chajewska K; Turek-Lepa E; Kwiatkowska D
    J Pharm Biomed Anal; 2015 Nov; 115():523-33. PubMed ID: 26311473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fast, comprehensive screening method for doping agents in urine by gas chromatography-triple quadrupole mass spectrometry.
    Van Eenoo P; Van Gansbeke W; De Brabanter N; Deventer K; Delbeke FT
    J Chromatogr A; 2011 May; 1218(21):3306-16. PubMed ID: 20970803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: A randomized, prospective, controlled multi-center trial.
    Schröder A; Albrecht U; Schnitker J; Reitz A; Stein R
    Neurourol Urodyn; 2016 Jun; 35(5):582-8. PubMed ID: 25754454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a GC-C-IRMS method for the confirmation analysis of pseudo-endogenous glucocorticoids in doping control.
    de la Torre X; Curcio D; Colamonici C; Molaioni F; Cilia M; Botrè F
    Drug Test Anal; 2015; 7(11-12):1071-8. PubMed ID: 26607312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A synopsis of the adverse analytical and atypical findings between 2005 and 2011 from the Doping Control Laboratory of Athens in Greece.
    Kioukia-Fougia N; Fragkaki A; Kiousi P; Leontiou IP; Dimopoulou H; Tsivou M; Lyris E; Georgakopoulos C
    J Anal Toxicol; 2014; 38(1):16-23. PubMed ID: 24194481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Black market products confiscated in Norway 2011-2014 compared to analytical findings in urine samples.
    Hullstein IR; Malerod-Fjeld H; Dehnes Y; Hemmersbach P
    Drug Test Anal; 2015; 7(11-12):1025-9. PubMed ID: 26607218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultra high performance liquid chromatography tandem mass spectrometry determination and profiling of prohibited steroids in human biological matrices. A review.
    Gosetti F; Mazzucco E; Gennaro MC; Marengo E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 927():22-36. PubMed ID: 23317577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-step silylation procedure for the unified analysis of 190 doping control substances in human urine samples by GC-MS.
    Kiousi P; Angelis YS; Lyris E; Koupparis M; Calokerinos AC; Atta-Politou J; Georgakopoulos CG
    Bioanalysis; 2009 Oct; 1(7):1209-24. PubMed ID: 21083047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mildronate (Meldonium) in professional sports - monitoring doping control urine samples using hydrophilic interaction liquid chromatography - high resolution/high accuracy mass spectrometry.
    Görgens C; Guddat S; Dib J; Geyer H; Schänzer W; Thevis M
    Drug Test Anal; 2015; 7(11-12):973-9. PubMed ID: 25847280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Oral Fesoterodine Be an Alternative for Intravesical Oxybutynin Instillations in Children with Neuropathic Bladder Dysfunction?
    van den Heijkant M; De Coster K; Jansen K; Bogaert G
    Urol Int; 2019; 103(2):202-210. PubMed ID: 31117096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of an open screening method for doping substances in urine by gas chromatography quadrupole time-of-flight mass spectrometry.
    Polet M; Van Gansbeke W; Van Eenoo P
    Anal Chim Acta; 2018 Dec; 1042():52-59. PubMed ID: 30428988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sports drug testing using complementary matrices: Advantages and limitations.
    Thevis M; Geyer H; Tretzel L; Schänzer W
    J Pharm Biomed Anal; 2016 Oct; 130():220-230. PubMed ID: 27040951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementary stable carbon isotope ratio and amount of substance measurements in sports anti-doping.
    Cawley AT; George AV
    Drug Test Anal; 2012 Dec; 4(12):897-911. PubMed ID: 22791679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbon isotope ratio analysis of endogenous glucocorticoid urinary metabolites after cortisone acetate and adrenosterone administration for doping control.
    Brooker L; Cawley A; Kazlauskas R; Goebel C; George A
    Drug Test Anal; 2012 Dec; 4(12):951-61. PubMed ID: 22987608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for benfluorex and its major urinary metabolites in routine doping controls.
    Thevis M; Sigmund G; Gougoulidis V; Beuck S; Schlörer N; Thomas A; Kwiatkowska D; Pokrywka A; Schänzer W
    Anal Bioanal Chem; 2011 Aug; 401(2):543-51. PubMed ID: 21116611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.
    Krause P; Fuhr U; Schnitker J; Albrecht U; Stein R; Rubenwolf P
    J Urol; 2013 Nov; 190(5):1791-7. PubMed ID: 23669567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.